. Author manuscript; available in PMC: 2010 Sep 1.

Published in final edited form as: Pediatr Blood Cancer. 2009 Sep;53(3):505–508. doi: 10.1002/pbc.21988

Table I.

Activity of Vorinostat against Cell Lines in the PPTP in Vitro Panel

Cell Line	Histology	IC₅₀ (μM)	Median IC₅₀ Ratio	IC₉₀ (μM)
RD	Rhabdomyosarcoma	6.06	0.24	51.75
Rh41	Rhabdomyosarcoma	0.88	1.63	2.81
Rh18	Rhabdomyosarcoma	9.77	0.15	21.60
Rh30	Rhabdomyosarcoma	1.72	0.83	4.36
BT-12	Rhabdoid	7.70	0.19	20.33
CHLA-266	Rhabdoid	2.49	0.58	15.45
TC-71	Ewing sarcoma	1.28	1.13	2.64
CHLA-9	Ewing sarcoma	1.30	1.11	4.50
CHLA-10	Ewing sarcoma	2.48	0.58	8.75
CHLA-258	Ewing sarcoma	0.61	2.37	12.22
GBM2	Glioblastoma	1.59	0.90	9.86
NB-1643	Neuroblastoma	1.44	1.00	61.32
NB-EBc1	Neuroblastoma	2.50	0.57	4.69
CHLA-90	Neuroblastoma	2.81	0.51	20.90
CHLA-136	Neuroblastoma	2.40	0.60	25.79
NALM-6	ALL	1.78	0.81	4.97
COG-LL-317	ALL	0.55	2.62	1.84
RS4;11	ALL	0.62	2.33	5.16
MOLT-4	ALL	0.68	2.11	2.42
CCRF-CEM	ALL	1.30	1.11	4.75
Kasumi-1	AML	0.80	1.79	3.67
Karpas-299	ALCL	0.48	2.97	2.12
Ramos-RA1	NHL	1.16	1.24	2.71
Median		1.44	1.00	2.46
Minimum		0.48	0.15	1.84
Maximum		9.77	2.97	61.32